PPT-Virologic and Immunologic Monitoring in HIV Care

and HIV Resistance Assays wwwhivguidelinesorg JUNE 2023 NYSDOH AIDS Institute Clinical Guidelines Program Purpose of These Guidelines Virologic and Immunologic Monitoring in HIV Care Guide clinicians in the use of HIV viral load testing at appropriate times and intervals to assess initial and ongoing ART responses. Despite this signi64257cant progress the number of children becoming newly infected with HIV remains unacceptably high About 240 000 210 000280 000 children became infected with HIV in 2013 The risk of a mother living with HIV passing the virus to h Results from SILEN-C1 in HCV genotype-1 treatment-naïve patients across different baseline factors. Disclosures. Introduction. SILEN-C1 trial. Virologic response. a. Methods. Baseline characteristics. May 21, . 2013. . For Audio: Dial-in#: 866.394.2346 Participant Code: 397 154 6368#. Welcome & . Overview, . 5 . mins. Maximizing Virologic Suppression, . 35 . mins. Panel Discussion . Guidelines for the Use of Antiretroviral Agents. in Adults and Adolescents. July . 2016. These slides were developed using the April 2015 treatment guidelines and were updated in . July 2016. . The intended audience is clinicians involved in the care of patients with HIV. . . 2014 Cycle (. June 2014–May 2015. ). Behavioral and Clinical Characteristics of . Persons Receiving Medical Care for HIV Infection. Medical Monitoring Project 2014 . Cycle. Surveillance system monitoring clinical outcomes and behaviors of adults receiving HIV medical care in the United States. Regional Capacity-Building Network. Based in Johannesburg, South Africa. Mission: Strengthen clinician capacity to deliver HIV, HBV, and HCV treatment . Partners include:. Supported through an educational grant from: . . HCV . testing and treatment. Lorenzo McFarland, DHA, MPH, MSW, PMP. USAF/Ret E-7 - Senior Program Manager. HIV, Hepatitis, and Related Conditions Program. Office of Specialty Care Services. Deputy Under Secretary for Health for Policy and Planning. When should it be done?. Professor of Medicine. UNC Chapel Hill School of Medicine. Joseph J. Eron, Jr., MD. Disclosures. Principal Investigator (Research Grants to University of North Carolina): GlaxoSmithKline/. reducing Viral transmission –VL monitoring in ART cohorts. 19/11/15. AWACC. Towards the 90/90/90 goals of the National programme for HIV/TB services. DOH-CAPRISA –UKZN- NHLS PROJECT. Dr.. Henry Sunpath. HIV1 and slower to progress to AIDS.. Most cases are due to type1.. Modes of transmission. 1-sexual.. 2- perinatal.. 3-parenteral(occupational and intravenous drug injection).. 4- blood transfusion.. Company Name. The Herpes Virus Family. Cytomegalovirus. Chapter 21. Etiology. Classified as a herpesvirus. Large enveloped DNA virus. Cell associated, spreads from cell to cell.. Epidemiology. Transmission: oral, respiratory or venereal.. Scientific and Medical Consultant. Adjunct Clinical Professor of Medicine, Division of Infectious Diseases. Keck School of Medicine of USC. David Alain . Wohl. , MD. Professor of Medicine, Division of Infectious Diseases. Pedro Cahn. Disclosures. Advisory. . boards. : Merck, . ViiV. . Healthcare. Research. . funds. : . Abbvie. , Merck, Richmond, . ViiV. . Healthcare. Speaker at . educational. . activities. : . Abbvie. Prepared by:. Brian R. Wood, MD. David H. Spach, MD. Last Updated: January 28, 2021. Dolutegravir (. Tivicay. ) . INSTI. Tivicay. . [TIV-eh-kay]. Dolutegravir. Treatment Naïve. : 50 mg once daily with or without food.